Mechanism of action
Tramadol exhibits a dual mechanism of action that distinguishes it from traditional opioids:
Opioid component: Tramadol and its active metabolite O-desmethyltramadol (M1) act as weak agonists at μ-opioid receptors. The M1 metabolite has significantly higher affinity for μ-receptors than the parent compound and contributes substantially to analgesic efficacy. This metabolite is formed by CYP2D6.
Monoaminergic component: Tramadol inhibits the reuptake of norepinephrine and serotonin in descending pain pathways, enhancing endogenous pain modulation. This non-opioid mechanism contributes approximately 30% of the analgesic effect.
The dual mechanism results in analgesic potency approximately one-tenth that of morphine. Because tramadol's efficacy depends partially on CYP2D6 metabolism, poor metabolizers may experience reduced analgesia, while ultra-rapid metabolizers may have enhanced opioid effects and toxicity risk.
- Tramadol has dual mechanism: weak μ-opioid agonist plus norepinephrine-serotonin reuptake inhibition
- Major risk is seizures, especially with SSRIs, bupropion, or doses exceeding recommendations
- Serotonin syndrome can occur when combined with SSRIs, SNRIs, MAOIs, or other serotonergic drugs
- CYP2D6 polymorphism affects efficacy and toxicity: poor metabolizers have less analgesia, ultra-rapid metabolizers risk toxicity
- Contraindicated in children <18 years post-tonsillectomy/adenoidectomy due to fatal respiratory depression risk in ultra-rapid metabolizers
- Naloxone may incompletely reverse tramadol toxicity and can precipitate seizures
- Physical dependence and withdrawal occur despite being a 'weaker' opioid; taper to discontinue
- Less constipation than traditional opioids due to non-opioid mechanism contributing to analgesia
Indications
Tramadol is indicated for:
- Moderate to moderately severe pain in adults requiring opioid-level analgesia
- Chronic pain conditions where non-opioid analgesics are insufficient
- Acute pain in settings where stronger opioids are not warranted
Tramadol is often used as a step-up from non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen before progressing to stronger opioids like oxycodone or morphine. It may be appropriate for musculoskeletal pain, postoperative pain, or neuropathic pain, though it is not first-line for neuropathic conditions.
Dosing follows the product label and should be individualized. Extended-release formulations are available for chronic pain management.
Pharmacokinetics
Absorption: Tramadol is rapidly absorbed after oral administration with peak plasma levels in 2 hours for immediate-release formulations. Bioavailability is approximately 75% and increases to 90% after repeat dosing.
Distribution: Volume of distribution is approximately 2.6-2.9 L/kg. Protein binding is about 20%.
Metabolism: Tramadol undergoes extensive hepatic metabolism. CYP2D6 converts tramadol to O-desmethyltramadol (M1), the active metabolite with higher μ-receptor affinity. CYP3A4 produces the N-desmethyl metabolite (M2). Genetic polymorphism in CYP2D6 significantly affects response—poor metabolizers have reduced efficacy while ultra-rapid metabolizers risk toxicity.
Elimination: Approximately 30% is excreted unchanged in urine, with metabolites accounting for the remainder. The elimination half-life is 6-7 hours for tramadol and 7-9 hours for M1. Renal impairment prolongs elimination. Dosage adjustment is required in severe renal or hepatic impairment.
Adverse effects
Common adverse effects
- Nausea and vomiting (most common, occurs in up to 40% of patients)
- Dizziness and vertigo
- Constipation (less than traditional opioids)
- Headache
- Somnolence
- Dry mouth
- Pruritus
Serious adverse effects
- Seizures: Tramadol lowers seizure threshold in a dose-dependent manner. Risk increases with doses exceeding recommendations, concomitant use of other serotonergic or seizure-threshold-lowering drugs (SSRIs, tricyclic antidepressants, antipsychotics, other opioids), and in patients with epilepsy or head trauma.
- Serotonin syndrome: Can occur when tramadol is combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, triptans, linezolid). Presents with agitation, hyperthermia, hyperreflexia, clonus, autonomic instability, and altered mental status.
- Respiratory depression: Although less than traditional opioids, respiratory depression can occur, especially in opioid-naive patients, elderly, or with concomitant CNS depressants.
- Hypoglycemia: Rare but reported, particularly in patients with renal impairment or other risk factors.
- Anaphylactoid reactions: Serious hypersensitivity reactions including angioedema have been reported.
- Dependence and withdrawal: Physical dependence can develop with chronic use. Abrupt discontinuation may precipitate withdrawal symptoms (anxiety, sweating, insomnia, rigors, pain, gastrointestinal symptoms).
- Adrenal insufficiency: Rare, with prolonged use.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to tramadol or opioids
- Acute intoxication with alcohol, hypnotics, centrally acting analgesics, opioids, or psychotropic drugs
- Concurrent or recent MAOI use (within 14 days)
- Acute or severe bronchial asthma in an unmonitored setting
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Children under 12 years for all indications
- Children under 18 years for post-tonsillectomy/adenoidectomy pain
- Breastfeeding in ultra-rapid CYP2D6 metabolizers
Warnings and precautions
Black Box Warnings: Include addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; CYP2D6 ultra-rapid metabolizers (particularly children); and interactions with benzodiazepines or other CNS depressants.
Pregnancy: Tramadol crosses the placenta. Prolonged use during pregnancy can cause neonatal opioid withdrawal syndrome. Use only if benefit justifies risk. Classified in pregnancy considerations requiring careful risk-benefit assessment.
Hepatic impairment: Metabolism is impaired; dosage adjustment required in severe impairment.
Renal impairment: Elimination is prolonged; dosage adjustment required when creatinine clearance is below 30 mL/min.
Seizure disorders: Use with extreme caution or avoid in patients with epilepsy or history of seizures.
Increased intracranial pressure or head injury: May obscure clinical course.
Elderly patients: Increased sensitivity to adverse effects; start with lower doses.
Suicidal or addiction-prone patients: Use with caution due to abuse potential.
Drug interactions
Major interactions
Serotonergic drugs: SSRIs, SNRIs, MAOIs, tricyclic antidepressants, triptans, 5-HT3 antagonists, linezolid, St. John's wort—increased risk of serotonin syndrome. MAOIs are contraindicated.
CNS depressants: Benzodiazepines, alcohol, other opioids, barbiturates, sedative-hypnotics—additive CNS depression, respiratory depression, and hypotension.
CYP2D6 inhibitors: Quinidine, fluoxetine, paroxetine, bupropion—reduce formation of active M1 metabolite, decreasing analgesic efficacy.
CYP3A4 inhibitors: Ketoconazole, erythromycin—may increase tramadol levels.
CYP3A4 inducers: Rifampin, carbamazepine, St. John's wort—may decrease tramadol efficacy.
Drugs that lower seizure threshold: Bupropion, antipsychotics, other opioids, tricyclic antidepressants—increased seizure risk.
Warfarin: Tramadol may enhance anticoagulant effect; monitor INR.
Ondansetron: May reduce tramadol's analgesic effect.
Digoxin and carbamazepine: Rare reports of increased levels or toxicity.
Patients should be counseled about the risk of combining tramadol with alcohol or other CNS-active substances.
Clinical pearls
- Tramadol is not a pure opioid: Its dual mechanism (weak μ-agonist plus SNRI activity) makes it distinct from traditional opioids. This results in a different side effect profile, notably lower constipation but higher seizure risk.
- Seizure risk is dose-dependent and multifactorial: Always consider cumulative seizure risk from concomitant medications (SSRIs, bupropion, antipsychotics) and patient history. The seizure threshold-lowering effect is one of the most high-yield testable features.
- CYP2D6 polymorphism matters clinically: Poor metabolizers (~7-10% of Caucasians) experience reduced analgesia. Ultra-rapid metabolizers (especially prevalent in certain populations) are at risk for opioid toxicity, including fatal respiratory depression in children.
- Serotonin syndrome is a real risk: Tramadol is often overlooked as a serotonergic agent. Always review concurrent SSRIs, SNRIs, or other serotonergic drugs. This interaction is a frequent exam question.
- Withdrawal can occur: Despite being a "weaker" opioid, tramadol can cause physical dependence. Withdrawal symptoms may include atypical features like anxiety and sensory disturbances in addition to typical opioid withdrawal. Taper gradually.
- Tramadol is a controlled substance in the United States (Schedule IV) due to abuse potential, though risk is lower than Schedule II opioids.
- Avoid in children post-tonsillectomy/adenoidectomy: Fatal respiratory depression has occurred in children who are ultra-rapid CYP2D6 metabolizers undergoing these procedures. This is a black box warning.
- Less constipation than traditional opioids: The monoaminergic mechanism results in relatively less effect on gastrointestinal motility compared to pure μ-agonists, which can be clinically advantageous.
- Not reversible by naloxone alone: Because only part of tramadol's effect is opioid-mediated, naloxone may incompletely reverse toxicity and can precipitate seizures.
- Monitor for hypoglycemia in susceptible patients: This is a rare but important adverse effect, particularly in diabetics or renally impaired patients.
TRAMADOL seizure risk factors: Tricyclics, SSRIs, Renal impairment, Antipsychotics, MAOIs, Age >75, Dose >400mg/day, Opioids (other), Low seizure threshold
Practice questions
1. A 58-year-old woman with chronic lower back pain presents to the emergency department with confusion, agitation, diaphoresis, and muscle rigidity. She started tramadol 3 days ago for pain management. Her medications include sertraline for depression and metoprolol for hypertension. Vital signs show temperature 39.2°C (102.6°F), heart rate 118/min, and blood pressure 168/95 mmHg. Physical examination reveals hyperreflexia and ocular clonus. Which of the following is the most likely diagnosis?
2. A 45-year-old man with a history of epilepsy well-controlled on valproic acid presents with new-onset tonic-clonic seizures. He recently started taking tramadol for chronic knee pain. He also takes fluoxetine for depression. Which of the following mechanisms best explains his seizures?
3. A 7-year-old child undergoes adenotonsillectomy. Post-operatively, the surgeon prescribes tramadol for pain management. The child's mother is concerned because she read that tramadol can be dangerous after this surgery. Which of the following best explains the contraindication?
Frequently asked questions
How does tramadol work?
Tramadol works through a dual mechanism of action. It acts as a weak agonist at μ-opioid receptors (especially through its active metabolite O-desmethyltramadol formed by CYP2D6) and inhibits the reuptake of norepinephrine and serotonin in descending pain pathways. This combination provides moderate analgesia with approximately one-tenth the potency of morphine. The monoaminergic component contributes about 30% of the pain relief.
What are the side effects of tramadol?
Common side effects include nausea (the most frequent, up to 40%), dizziness, constipation, headache, and drowsiness. Serious side effects include seizures (especially at high doses or with SSRIs/other serotonergic drugs), serotonin syndrome when combined with antidepressants, respiratory depression, and hypoglycemia. Tramadol causes less constipation than traditional opioids. Physical dependence can develop with chronic use, and abrupt discontinuation may cause withdrawal symptoms.
Is tramadol a controlled substance?
Yes, tramadol is a Schedule IV controlled substance in the United States due to its abuse and dependence potential, though this risk is lower than Schedule II opioids like oxycodone or morphine. Despite being a 'weaker' opioid, tramadol can cause physical dependence and withdrawal symptoms with chronic use. It requires a prescription and is subject to monitoring, though it has fewer prescribing restrictions than higher-schedule opioids.
Tramadol vs codeine — what is the difference?
Both tramadol and codeine are weaker opioids used for moderate pain, but they differ significantly. Tramadol has a dual mechanism (weak μ-opioid agonist plus SNRI activity) while codeine is a pure opioid prodrug converted to morphine by CYP2D6. Tramadol carries higher seizure risk and can cause serotonin syndrome with antidepressants, whereas codeine does not. Both depend on CYP2D6 for efficacy. Tramadol causes less constipation and respiratory depression than codeine but has more drug-drug interactions due to its serotonergic effects.
Can you take tramadol with antidepressants?
Combining tramadol with antidepressants requires caution due to serious interaction risks. Tramadol with SSRIs, SNRIs, MAOIs, or tricyclic antidepressants increases the risk of serotonin syndrome (a potentially fatal condition) and lowers seizure threshold. MAOIs are contraindicated within 14 days of tramadol. If combination is necessary, use the lowest effective doses and monitor closely for serotonin syndrome symptoms: agitation, confusion, hyperthermia, muscle rigidity, hyperreflexia, and autonomic instability. Many clinicians avoid this combination or choose alternative analgesics.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02AX02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.